Orphanbiotec | Natural Solutions
15234
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-15234,ajax_fade,page_not_loaded,,qode-title-hidden,side_area_uncovered_from_content,qode-child-theme-ver-1.0.0,qode-theme-ver-10.1.1,wpb-js-composer js-comp-ver-5.0.1,vc_responsive
LayerSlider encountered a problem while it tried to show your slider.Please make sure that you've used the right shortcode or method to insert the slider, and check if the corresponding slider exists and it wasn't deleted previously.

TRULY

focused on

Rare (orphan) Diseases

Orphanbiotec AG is a socially responsible, research-based
pharmaceutical enterprise specializing in Rare Diseases.
Enabled by our partners, we build bridges for people in need
and affordable health care of the future.

IMPLICT

social

commitment

Orphanbiotec AG is a socially responsible, research-based
pharmaceutical enterprise specializing in Rare Diseases.
Enabled by our partners, we build bridges for people in need
and affordable health care of the future.

ESTABLISHING

treatments

based on natural principles

Orphanbiotec AG is a socially responsible, research-based
pharmaceutical enterprise specializing in Rare Diseases.
Enabled by our partners, we build bridges for people in need
and affordable health care of the future.

SUSTAINABLE

financial

impact

Orphanbiotec AG is a socially responsible, research-based
pharmaceutical enterprise specializing in Rare Diseases.
Enabled by our partners, we build bridges for people in need
and affordable health care of the future.

Find out more about our crowdfunding campaign:

who we are

Orphanbiotec works on the development and implementation of new medications for Rare Diseases. Our nature based pharmaceutical solutions create affordable therapies for Rare Diseases in a sustainable and profitable manner through the repositioning of approved substances. The company was founded in January 2009. Orphanbiotec AG is a Swiss Start-up company, which works in a unique hybrid partnership with the charitable Foundation Orphanhealthcare.

Orphanbiotec engages in delivering sustainable, financial and social impact to patients & investors.

What we do

We develop innovative and affordable Orphan Drugs for diagnosis and therapy of Rare Diseases.

Rare means nearly 5 out of 10.000 healthy individuals can be affected. So rare is not rare, since more than 7000 diseases are know today and approx. In Europe there are 30 M people living with a rare disease. About 75 % out of them are children.

Financial impact

How do we generate our impact.

  1. Saving costs by using approved and safe molecules from natural resources.
  2. Reducing cost by implementing partner from R&D and development.
  3. Sharing costs by benefitting from Grant-giving-Partner.
  4. Working in partnership with Foundation Orphanhealthcare to implement sponsors, increase visibility and patient empowerment by SROI (Social Return on Investment).

Natural Solutions

We are approaching active principles present in nature. Many are used for generations by healer or complementary treatments and safe, but underestimated for additional and useful effects. And many of the natural principles are not even discovered yet.

Awards

We are proud to be winner of:

  1. 2015 European Corporate Excellence Award Winner
  2. 2014 Nominee of W.A. De Vigier Price
  3. 2011 Winner of SEIF (Social Entrepreneurship Foundation Award Switzerland)

Do you want our newsletter?

Partners